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Chronic lymphocytic leukaemia (CLL) represents an abnormal clonal expansion of 
mature antigen-experienced CD5+ B1a cells (Chiorazzi et al, 2005), which present with 
a highly heterogeneous clinical course depending on associated chromosomal 
aberrations, somatic mutations within the immunoglobulin variable heavy chain genes 
(IGHV), and surface CD38 or intracytoplasmic ZAP-70 expression. Since key signalling 
components of the B-cell receptor (BCR) are relevant contributors to the variable 
clinical behaviour of CLL (Stevenson et al, 2011) we explored the influence of 
functionally relevant germline CD5 variants on CLL prognosis. The rationale behind 
this is that CD5, a lymphocyte receptor normally expressed in all T cells and the B1a 
cell subset, is considered a negative modulator of intracellular signalling mediated by 
the antigen-specific receptor present on both T (TCR) and B1a (BCR) cells, to which 
physically associates (Soldevila et al, 2011). Moreover, in both normal and leukemic B 
cells, CD5 signalling is relevant for production of the B1a cell autocrine growth factor 
IL-10, and for acquisition of a common gene transcription signature (Gary-Gouy et al, 
2007). 
The existence of common nonsynonymous CD5 single nucleotide polymorphisms 
(SNPs) has been recently reported (Carnero-Montoro et al, 2012). Two of them, 
rs2241002 (C>T) and rs2229177 (C>T), coding for amino acid changes at the 
extracellular (P224>L) and cytoplasmic (A471>V) regions of CD5, respectively, 
conform haplotypes relevant to CD5-mediated signal transduction. Accordingly, 
homozygous carriers of the ancestral P224-A471 (CC) haplotype are less efficient than 
the more recently derived P224-V471 (CT) haplotype in providing inhibitory signals to 
TCR-mediated activation responses and are associated with more clinically aggressive 
forms of autoimmune disease (Cenit et al, 2014). In light of this evidence, the putative 
influence of CD5 SNPs rs2241002 and rs2229177 on clinical outcome of CLL patients 
from our Hospital was explored.  
In total, 935 patients from our CLL database had DNA samples available for study. 
Median age was 63 years (range, 18-98 years) at CLL diagnosis. Binet stage was A in 
83% of patients, B in 12% of patients, and C in 5% of patients. Results of FISH, CD38 
expression, ZAP70 expression and IGHV mutation status were available in 81%, 77%, 
83% and 79% of patients. Median follow-up was 34 months (range, 1-158) from 
frontline therapy and 93 months (range, 1-471) from diagnosis. Four hundred and 
seventeen (44%) patients required therapy at least once. The most commonly used 
chemotherapeutic agents were fludarabine, alone or in combination (37%), 
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chlorambucil (28%), COP/CHOP chemotherapy (17%) and cladribine (6%). Only 10% 
of these patients received rituximab as frontline therapy. The A471V genotypes CC, CT 
and TT were observed in 202 (22%), 432 (48%) and 269 (30%) patients, respectively. 
Regarding P224L, genotypes CC, CT and TT were documented in 575 (63%), 316 
(34%) and 29 (3%) patients, respectively. There were no significant differences across 
all different A471V genotypes in terms of age, sex, prognostic factors, therapy 
administered or follow-up. 
Median PFS from frontline therapy was 46 months (95% confidence interval: 38-52 
months) for those patients who required therapy. Known adverse prognostic factors, 
such as high ZAP-70 expression (P<0.001), unmutated IGHV status (P<0.001), adverse 
FISH aberrations (P=0.002) and high CD38 expression (P=0.007) had a significant 
impact on PFS when the entire cohort was analysed. The A471V polymorphism had a 
trend towards a significant impact on PFS (P=0.052), while P224L had no significant 
effect on this outcome. 
Next, only patients who required therapy but were homozygous for the most prevalent 
P224L genotype (P224P, CC) were selected for evaluation of the impact of the A471V 
polymorphism. Baseline characteristics of this selected population of patients are 
displayed in Table I. Age, sex, prognostic factors, therapy and follow-up were well 
balanced across all three genotypes. High ZAP-70 (P=0.001) and CD38 expression 
(P=0.008), and unmutated IGHV status (P<0.001) were equally significant in terms of 
PFS in this selected population, as was the A471V genotype. Indeed, patients carrying a 
CC or CT A471V genotype had a significantly prolonged median PFS compared to TT 
carriers (51 vs. 41 months, P=0.024) (Fig. 1A). This prognostic impact was particularly 
evident in patients with mutated IGHV (110 vs. 40 months, P=0.028), and not in 
patients with unmutated IGHV (36 vs. 47 months, P=1.0) (Fig. 1B). A multivariate Cox 
regression analysis comprising CD38 and ZAP-70 expression, A471V polymorphism 
and FISH aberrations was performed in this subgroup of patients with mutated IGHV, 
revealing that both the A471V polymorphism (hazard ratio [HR] = 3.7; 95% confidence 
interval = 1.21-11.3; P=0.21) and FISH aberrations (HR=3.5; 95% CI=1.08-11.3; 
P=0.036) had independent prognostic value in terms of PFS. 
The overall survival was also analyzed but neither A471V, P224L nor the combined 
effect had any significant impact on that outcome, although there was a trend towards a 
significantly longer overall survival for patients carrying a CC or CT genotype for 
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A471V but only in patients with P224P (CC) genotype and mutated IGHV genes 
(P=0.073). 
The present results indicate that CLL patients either homo- or heterozygous for the 
ancestral CD5 allele A471 (C) have significantly prolonged PFS in less aggressive cases 
presenting mutated IGHV. They are reminiscent of a previous single report (Sellick et 
al, 2008) showing that the more recently derived V471 (T) allele was associated with 
shorter PFS independently of IGHV mutational status. In our study, this effect was 
particularly evident when we restricted the analysis to patients with the P224P (CC) 
genotype and mutated IGHV, and non-existent in patients with unmutated IGHV. 
Interestingly, most unmutated IGHV CLL cases contain mutations in driver genes, most 
of them conferring a bad prognosis and faster progression (Puente et al, 2015). By 
contrast, most mutated IGHV cases have mutations in better prognosis drivers such as 
MYD88 or del(13q14), resulting in a less aggressive disease. These differences might 
allow the observation of the protecting effect of CD5 polymorphisms only in mutated 
IGHV cases. On the other hand, only 10% of patients received a rituximab-based 
regimen, which may or may not abrogate the impact of the polymorphism, and is 
therefore the main limitation of our study. 
How the CD5 A471V variants influence the natural behaviour of CLL cells is an 
unresolved question. However, the lower signal transducing capability of the A471 
variant (Carnero-Montoro et al, 2012; Cenit et al, 2014) could result in either 1) a lower 
capability for negatively modulating the antigen-receptor (BCR) mediated signalling, or 
2) a lower anti-apoptotic signalling (Tibaldi et al, 2011). Whatever the case, the present 
results support the notion that CD5 is not only a phenotypic marker but a relevant player 
in CLL cell biology as demonstrated by the influence of germline-defined functional 
CD5 variants on CLL outcome. 
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Table I. Baseline characteristics according to the A471V polymorphism of patients who 
required CLL-specific therapy and had a homozygous P224P (CC) genotype  
 
A471V genotype CC (n = 156) CT (n = 249) TT (n = 141) P value 
Age (y), median (range) 65 (32-93) 64 (28-98) 63 (18-94) .855 
Sex, % male/female 58/42 53/47 60/40 .280 
Binet stage B or C, n (%) 26 (17) 40 (16) 14 (10) .180 
Serum beta2-microglobulin 
(mg/l), median (range) 
1.9 (1.0-33) 2.1 (1.0-17) 2.2 (1.5-11) .129 
Positive CD38 expression, n (%) 33 (27) 59 (31) 27 (24) .445 
Positive ZAP70 expression, n (%) 34 (25) 49 (24) 36 (30) .429 
Unmutated IGHV gene, n (%) 47 (37) 66 (33) 45 (40) .464 
FISH aberrations (Döhner’s 
hierarchical model): 
   .502 
Favorable (13q-,+12, none) 105 (81) 180 (86) 96 (83)  
Unfavorable (11q-, 17p-) 24 (19) 29 (14) 19 (17)  
Frontline therapy:    .412 
Chlorambucil, n (%) 21 (32) 29 (28) 14 (22)  
CHOP/COP, n (%) 11 (17) 14 (14) 6 (10)  
Fludarabine mono/combo, n (%) 22 (33) 36 (35) 21 (33)  
Cladribine monotherapy, n (%) 5 (8) 4 (4) 6 (10)  
RCHOP, n (%) 1 (1) 0 (0) 2 (3)  
RFC/RFCM, n (%) 2 (3) 10 (10) 5 (8)  
Others, n (%) 4 (6) 9 (9) 9 (14)  
Follow-up from frontline therapy 
(mo), median (range) 
49 (4-150) 34 (3-158) 28 (4-143) .056 
Follow-up from CLL diagnosis 
(mo), median (range) 
101 (3-314) 87 (4-463) 86 (4-277) .313 
 
Abbreviations: FISH, fluorescent in-situ hybridization; B-CLL, B-cell chronic 
lymphocytic leukaemia; IGHV, immunoglobulin heavy chain variable region; CHOP, 
cyclophosphamide, doxorubicin, vincristine and prednisone; COP, cyclophosphamide, 
vincristine and prednisone; RCHOP, rituximab, cyclophosphamide, doxorubicin, 
vincristine and prednisone; RFCM, rituximab, fludarabine, cyclophosphamide and 
mitoxantrone; RFC, rituximab, fludarabine and cyclophosphamide. 
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 FIGURE LEGENDS 
 
Fig. 1. (A) Progression-free survival according to the A471V polymorphism in patients 
who required CLL-specific therapy and had a homozygous P224P (CC) genotype (P = 
0.024). (B) Progression-free survival according to the A471V polymorphism in patients 
who required CLL-specific therapy, and had a homozygous P224P (CC) genotype and 
mutated IGHV (P = 0.028). 
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